BeaconEquity.com releases investment report on Cell Therapeutics

BeaconEquity.com announces an investment report featuring biotech company Cell Therapeutics Inc. (Nasdaq:CTIC). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision. 

The full report is available at: http://www.beaconequity.com/i/CTIC

Get our alerts BEFORE the rest of the market.  Follow us on Twitter: https://twitter.com/BeaconEquity

Cell Therapeutics Inc. (CTIC) develops, acquires and commercializes treatments for cancer. It focuses on building a biopharmaceutical company with a diversified portfolio of oncology drugs. Its research, development, acquisition and in-licensing activities concentrate on identifying and developing less toxic ways to treat cancer.

Message Board Search for CTIC: http://www.boardcentral.com/boards/CTIC

In the report, the analyst notes:

"For the quarter ended December 31, 2009, total net operating expenses were approximately $26.2 million, compared to $11.2 million for the same period in 2008. The increase in total net operating expenses was mainly a result of a non-cash equity based compensation expense of $11.7 million for the quarter ended December 31, 2009, and a $9.4 million gain on the sale of Zevalin to a 50/50 owned joint venture with Spectrum that was recognized in the quarter ended December 31, 2008.

"CTIC recently announced that it has entered into an agreement to sell $20 million of shares of its Series 4 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to three institutional investors. Each share of Series 4 Preferred Stock is convertible at the option of the holder, at any time during its existence, into 2,000 shares of common stock at a conversion price of $0.50 per share of common stock, for a total of 40,000,000 common shares."